Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
The antiviral drugs market is anticipated to grow at a CAGR of 6.3% during the period 2022-2035, claims Roots Analysis
November 01, 2022 15:00 ET
|
Roots Analysis
London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings. The recent COVID-19 pandemic has...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
November 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Global Conjunctivitis Treatment Market Size to Reach USD 6.1 Billion by 2031: Allied Market Research
October 03, 2022 13:14 ET
|
Allied Market Research
Portland, OR, Oct. 03, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Conjunctivitis Treatment Market generated $4.2 billion in 2021, and...
Pneumonia Therapeutics Market Estimated to Generate $3,147.7 Million and Grow at 8.2% CAGR by 2027 Post Covid-19 Pandemic | Confirmed by Research Dive
September 27, 2022 09:01 ET
|
Research Dive
New York, USA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global pneumonia therapeutics market is estimated to generate a revenue of $3,147.7 million...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
September 14, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
September 13, 2022 08:00 ET
|
Pardes Biosciences, Inc
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel...
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120
June 09, 2022 07:00 ET
|
Exavir Therapeutics
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...